Board of Directors and Management Team

Demonstrating our breadth of experience across science, corporate and financial disciplines

Board

Suzanne Dilly Dr Suzanne Dilly
Chief Executive Officer
Suzanne Dilly

Dr Suzanne Dilly

Chief Executive Officer

Dr Suzanne Dilly is an experienced entrepreneurial scientist. After commercialising her Chemical Biology post-doctoral research in the University of Warwick spin-out, a2sp Limited, Suzanne was awarded a prestigious Royal Society of Edinburgh Enterprise Fellowship, during which formal commercial and entrepreneurial training completed her transition from lab to boardroom.

Completing commercial transactions to progress projects through multiple companies, Suzanne has been working in small company virtual biotechs since 2006.

LinkedIn Profile
Kevin Cox Dr Kevin Cox
Non-Executive Chairman
Kevin Cox

Dr Kevin Cox

Non-Executive Chairman

Kevin has over 25 years’ experience in the life science industry. Serving as CEO of high growth biotechnology businesses, he has extensive experience in strategy, corporate development, M&A, financing and joint ventures. With a passion for improving translational science, Kevin has strong links to government, funding bodies and academia, and has contributed to a number of public sector advisory committees. Kevin currently has non-executive roles with Biorelate Limited, Syndermix SA, the British Neuroscience Association and Biotaspheric.

LinkedIn Profile
Gerry Desler Mr Gerry Desler
Chief Financial Officer
Gerry Desler

Mr Gerry Desler

Chief Financial Officer

Gerry is a chartered accountant, who qualified in 1968 with a City firm, before becoming a partner (1970) and Senior Partner (1985). During his time in the City, he has specialised in consultancy work, much of it involving funding and venture capital.

Gerry was previously the Finance Director of Premier Management Holdings plc, an AIM listed company and is on the board of a number of private companies. Gerry also holds positions as Company Secretary at Prospex Oil and Gas Plc both AIM listed companies.

Kevin Alexander Mr Kevin Alexander
Non-Executive Director
Kevin Alexander

Mr Kevin Alexander

Non-Executive Director

Kevin is a qualified solicitor in England and an attorney in New York and he was a partner at major law firms in both London and the United States for over 25 years. Since leaving the law he has been involved in forming and managing various businesses, both private and public. Kevin is a director of ValiRx Plc, and joined the board in September 2006. He has an MA in law from Cambridge University.

Martin Lampshire Mr Martin Lampshire
Non-Executive Director
Martin Lampshire

Mr Martin Lampshire

Non-Executive Director

Martin started his career in Lloyds Bank’s Commercial Services division in 1989 after completing the ACIB qualification. He has over thirty years’ experience in Corporate Broking, assisting in a variety of equity raises including IPOs, secondary fundraisings, vendor and private placings across a variety of sectors. 

He has also worked in a number of overseas financial centres including Hong Kong, Singapore, Kuala Lumpur and Dubai. Martin is currently an Executive Director of Global Resources Investment Trust Plc and a Non-Executive Director of Bould Opportunities Plc.

LinkedIn Profile

Management Team

Kumar Nawani Mr Kumar Nawani
Head of Operations
Kumar Nawani

Mr Kumar Nawani

Head of Operations

Kumar has been working over 20 years in international trade, client & vendor management, business development, brand development, e-commerce, procurement, IT management & compliance roles with established public and private companies here in the UK and previously in Hong Kong.

Kumar has been with the ValiRx Group since January 2008 and as an active member of the ValiRx management team.

 

 

LinkedIn Profile
Mark Treharne Mr Mark Treharne
Corporate Development Manager
Mark Treharne

Mr Mark Treharne

Corporate Development Manager

Mark began his career in the City in 2011 and has worked in Corporate Broking and Equity sales working for numerous different firms including Daniel Stewart, Northland Capital Partners and Pello Capital. His role includes enhancing the reputation of the company within the City and working closely with City firms to identify new therapeutic assets to incorporate into the ValiRx portfolio.

LinkedIn Profile